CPC "biocon" Llc Pharmaceutical Import Profile — Ukraine (DGFT 2022–2026)

Name: CPC "biocon" Llc Pharmaceutical Import Records from India — 8 Products, $2.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

CPC "biocon" Llc — Pharmaceutical Importer Profile (2026) | 8 Products, $2.1M Trade | TransData Nexus

CPC "biocon" Llc

Pharmaceutical Importer · Ukraine · Oncology Focus · $2.1M Total Trade · DGFT Verified

CPC "biocon" Llc is a pharmaceutical importer based in Ukraine with a total trade value of $2.1M across 8 products in 3 therapeutic categories. Based on 56 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. CPC "biocon" Llc sources from 1 verified Indian supplier, with Nv Remedies Private Limited accounting for 100.0% of imports.

CPC "biocon" Llc — Import Portfolio & Supplier Network

CPC "biocon" Llc import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to CPC "biocon" Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Nv Remedies Private Limited	$3.1M	164	100.0%

CPC "biocon" Llc sources from 1 verified Indian supplier across 111 distinct formulations. The sourcing is highly concentrated — Nv Remedies Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does CPC "biocon" Llc Import?

Formulation	Value	Ships
Paclitaxel injection USP 100MG/16.7ML Each ML contains: paclitaxel...6 MG,polyoxyl 35 caster oil...527 MG	$113.9K	3
Oxol solution for injection 100MG/50ML oxaliplatin solution for injection 100 MG/50ML 1ML contains:oxaliplatin USP 2 MG	$113.0K	3
Docetaxel 80MG/2 ML con.for SOL.for inf.e.ML of con.cont:docetaxel (as anhy.)40MG ethanol (as anhy.)326 MG(docet 80 MG)	$106.0K	4
Docetaxel injection concentrate (80 MG/2.0 ML) Each 0.5 ML contains : docetaxeltrihydrate eqv. to anhydrous docetaxel..	$92.7K	2
Mili nosik oral drops e.ML	$75.5K	3
Oxol solution for injection 50MG/25ML oxaliplatin solution for injection 50MG/25ML,1ML solution con:oxaliplatin USP 2 MG	$67.4K	3
Docetaxel 80MG/2 ML concentrate for solution for infusion Each ML of concentratecontains:docetaxel(as anhydrous).40 MG	$62.5K	2
Fluorouracil solution for injection 500MG/10 ML Each ML contains:fluorouracil.50 MG,water for injection q.s.(flura -5)	$55.5K	6
Flura-5 solution for injection	$53.5K	2
Meratin combi vaginal TAB. e.vaginal,TAB.cont.ornidazole 500MG neomycin sulp.100MG ,nystatin 100 000 IU prenisolone 3MG	$52.6K	2
Docetaxel 20MG/0.5 ML conce.for solu.forinf.e.ML of con.cont:docetaxel(as anh.)40 MG ethanol(as anh.)326 MG(docet 20MG)	$52.3K	3
Lyophilized pwr for SOL.for INJ.15	$50.0K	1
Fluorouracil solution for injection or	$50.0K	1
Cytarabine solution for injection 1000MG	$50.0K	1
Docetaxel injection concentrate (20MG/0.	$50.0K	1

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Docetaxel	Oncology	$707.3K	18	1.8%	10
2	Carboplatin	Oncology	$350.0K	7	0.4%	5
3	Fluorouracil	Oncology	$350.0K	7	2.9%	7
4	Bleomycin	Advanced Oncology	$235.7K	7	4.2%	5
5	Paclitaxel	Oncology	$150.0K	3	0.2%	18
6	Ornidazole	Advanced Antibiotics	$135.0K	7	0.8%	15
7	Cytarabine	Advanced Oncology	$133.0K	5	1.2%	18
8	Dacarbazine	Advanced Oncology	$62.8K	2	4.4%	4

CPC "biocon" Llc imports 8 pharmaceutical products across 3 categories into Ukraine totaling $2.1M.

CPC "biocon" Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

CPC "Biocon" LLC is a Ukrainian pharmaceutical importer and buyer specializing in the acquisition of finished pharmaceutical formulations. Headquartered in Shchaslyve, Kyiv Oblast, Ukraine, the company operates as a key player in the nation's pharmaceutical distribution network. Established in 1997, CPC "Biocon" LLC has developed a reputation for its efficient logistics and warehousing services, catering to both domestic and international pharmaceutical companies. The company is part of the Biocon Group, a conglomerate involved in the wholesale and retail pharmaceutical sectors in Ukraine.

CPC "Biocon" LLC's role in Ukraine's pharmaceutical distribution is multifaceted. It serves as a primary wholesaler, sourcing a diverse range of pharmaceutical products to meet the needs of the Ukrainian market. The company's strategic focus on importing finished pharmaceutical formulations enables it to provide a comprehensive portfolio of products across various therapeutic categories, thereby contributing significantly to the availability and accessibility of essential medications within the country.

2Distribution Network

CPC "Biocon" LLC operates a centralized distribution network with its primary warehouse located in Shchaslyve, Kyiv Oblast, Ukraine. This facility is strategically positioned to facilitate efficient logistics and distribution throughout the country. The company's logistics capabilities include customs clearance, storage, handling, and transportation services, ensuring the seamless movement of pharmaceutical products from international suppliers to the Ukrainian market. By leveraging its modern warehousing infrastructure and comprehensive logistics services, CPC "Biocon" LLC effectively manages the supply chain, maintaining a steady flow of pharmaceutical products to meet domestic demand.

3Industry Role

In Ukraine's pharmaceutical supply chain, CPC "Biocon" LLC functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in ensuring the availability of a wide range of medications across various therapeutic categories. Its operations encompass the procurement, storage, and distribution of pharmaceutical products, thereby bridging the gap between global manufacturers and the Ukrainian healthcare system. This position underscores CPC "Biocon" LLC's integral role in maintaining the efficiency and reliability of the pharmaceutical supply chain within Ukraine.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — CPC "biocon" Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CPC "Biocon" LLC demonstrates a high degree of supplier concentration, with all its pharmaceutical imports originating from a single supplier: NV Remedies Private Limited. This exclusive sourcing strategy has resulted in a total import value of $3.1 million USD over 164 shipments, accounting for 100% of the company's pharmaceutical imports from India. The top five imported products—Docetaxel, Carboplatin, Fluorouracil, Bleomycin, and Paclitaxel—collectively represent 84.4% of the total import value, indicating a focused product portfolio.

While this concentrated sourcing approach may offer benefits such as streamlined procurement processes and potentially favorable pricing, it also introduces risks associated with over-reliance on a single supplier. Any disruptions in NV Remedies Private Limited's operations could significantly impact CPC "Biocon" LLC's ability to meet market demand. The company's shipment data, however, suggests a stable and ongoing relationship with NV Remedies, as evidenced by the consistent volume of imports over the years. Nonetheless, the lack of diversification in sourcing warrants consideration of potential contingency plans to mitigate supply chain vulnerabilities.

2Supply Chain Resilience

CPC "Biocon" LLC's supply chain resilience is closely tied to its exclusive partnership with NV Remedies Private Limited. The company's import data indicates a consistent flow of pharmaceutical products from this sole supplier, suggesting a stable and reliable relationship. However, the absence of backup suppliers introduces a level of vulnerability; any disruptions at NV Remedies could lead to significant supply chain challenges. The company's focus on a limited number of therapeutic categories—Oncology, Advanced Oncology, and Advanced Antibiotics—further concentrates its supply chain, potentially limiting its ability to adapt to sudden changes in market demand or supply conditions. To enhance resilience, CPC "Biocon" LLC may consider diversifying its supplier base and expanding its product portfolio to mitigate risks associated with over-reliance on a single source.

Importing Pharmaceuticals into Ukraine — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ukraine

1Regulatory Authority & Framework

In Ukraine, the State Service of Ukraine on Medicines and Drugs Control (SMDC) is the primary regulatory authority overseeing the pharmaceutical sector. The SMDC is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products within the country. Key legislation governing pharmaceutical imports includes the Law of Ukraine on Medicinal Products, which outlines the requirements for the registration, importation, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a Certificate of Good Manufacturing Practice (GMP) from the SMDC, followed by the registration of the product, which includes submission of necessary documentation such as clinical trial data, stability studies, and labeling information.

2Import Licensing & GMP

Import licensing requirements in Ukraine stipulate that pharmaceutical importers must obtain an import license from the SMDC, demonstrating compliance with national regulations and standards. Recognition of Good Manufacturing Practice (GMP) certificates is crucial; certificates from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S) are generally accepted. Indian exporters seeking to supply CPC "Biocon" LLC must ensure that their manufacturing facilities hold valid GMP certifications from recognized authorities. Additionally, obtaining wholesale distribution authorization from the SMDC is necessary to legally distribute pharmaceutical products within Ukraine.

CPC "biocon" Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CPC "Biocon" LLC's focus on importing pharmaceutical products in the oncology and advanced antibiotics therapeutic categories aligns with the growing demand for cancer treatments and advanced antibiotic therapies in Ukraine. The market demand is driven by an increasing prevalence of cancer cases and the need for effective antibiotic treatments to combat resistant infections. By concentrating on these therapeutic areas, CPC "Biocon" LLC positions itself to meet critical healthcare needs and capitalize on market opportunities within the Ukrainian pharmaceutical sector.

2Sourcing Profile

CPC "Biocon" LLC's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology and advanced antibiotics categories. The company's exclusive partnership with NV Remedies Private Limited reflects a preference for established suppliers with a proven track record in manufacturing high-quality pharmaceutical formulations. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a strategic sourcing destination for CPC "Biocon" LLC.

3Market Positioning

Seller's Guide — How to Become a Supplier to CPC "biocon" Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with CPC "Biocon" LLC by offering complementary products or alternative formulations within the oncology and advanced antibiotics therapeutic categories. By diversifying its supplier base, CPC "Biocon" LLC can mitigate risks associated with over-reliance on a single source and enhance its product portfolio to better serve the Ukrainian market. Indian exporters can explore this opportunity by ensuring compliance with Ukrainian regulatory standards and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters seeking to supply CPC "Biocon" LLC and the Ukrainian market must ensure that their manufacturing facilities hold valid GMP certifications from recognized authorities such as the EU, WHO, or PIC/S. Additionally, compliance with Ukrainian labeling and packaging requirements, including the use of the Ukrainian language, is essential. Exporters should also be prepared to navigate

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — CPC "biocon" Llc

What products does CPC "biocon" Llc import from India?

CPC "biocon" Llc imports 8 pharmaceutical products across 3 categories. Top imports: Docetaxel ($707.3K), Carboplatin ($350.0K), Fluorouracil ($350.0K), Bleomycin ($235.7K), Paclitaxel ($150.0K).

Who supplies pharmaceuticals to CPC "biocon" Llc from India?

CPC "biocon" Llc sources from 1 verified Indian suppliers. The primary supplier is Nv Remedies Private Limited (100.0% of imports, $3.1M).

What is CPC "biocon" Llc's total pharmaceutical import value?

CPC "biocon" Llc's total pharmaceutical import value from India is $2.1M, based on 56 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does CPC "biocon" Llc focus on?

CPC "biocon" Llc imports across 3 categories. The largest: Oncology (73.3%), Advanced Oncology (20.3%), Advanced Antibiotics (6.4%).

Get Full CPC "biocon" Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.